ERBB2 and hepatocellular carcinoma: In summary, while research on ERBB2 in HCC is still relatively limited, our study has found that the combination of ERBB2 inhibitor Afatinib with Anti pd1 can significantly enhance the therapeutic effect of HCC (Figure 7).